ReviewAn expanding world of new psychoactive substances—designer benzodiazepine (cas 12794-10-4)s
-
Add time:08/28/2019 Source:sciencedirect.com
The abuse of new psychoactive substances (NPS) has been increasing dramatically since the late 2000s worldwide. Between 2009 and 2017, a total of 803 individual NPS were reported to the United Nations Office of Drugs and Crime by 111 countries and territories. Although the most popular compounds are synthetic cannabinomimetics and psychostimulatory derivatives of cathinone (so-called β-keto-amphetamines), novel benzodiazepines have recently emerged on the recreational drug market. The misuse/abuse of “designer benzodiazepines” (DBZD), a common name for the benzodiazepine class NPS, has become an increasing problem in many countries. The DBZD group includes pharmaceutical drug candidates that have never been approved for medical use, compounds that were synthesized by a simple structural modification of a registered drug, and some active metabolites of registered benzodiazepines. This survey presents members of the DBZD group, describes the epidemiological trends and clinical effects associated with DBZD use, and discusses available data on their metabolism. Special emphasis is given to cases of intoxications involving these compounds.
We also recommend Trading Suppliers and Manufacturers of benzodiazepine (cas 12794-10-4). Pls Click Website Link as below: cas 12794-10-4 suppliers
Prev:ReviewThe epidemiology of benzodiazepine (cas 12794-10-4) misuse: A systematic review
Next:7New benzodiazepine (cas 12794-10-4)s for sedation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Inappropriate prescription of benzodiazepine (cas 12794-10-4)s in acutely hospitalized older patients09/04/2019
- Original StudyAssociation of benzodiazepine (cas 12794-10-4) and Anticholinergic Drug Usage With Incident Dementia: A Prospective Cohort Study of Community-Dwelling Older Adults09/03/2019
- Brief Reportbenzodiazepine (cas 12794-10-4)s vs barbiturates for alcohol withdrawal: Analysis of 3 different treatment protocols09/02/2019
- Influence of Abuse History on Concurrent benzodiazepine (cas 12794-10-4) and Opioid Use in Chronic Pain Patients09/01/2019
- ReviewThe benzodiazepine (cas 12794-10-4) Binding Sites of GABAA Receptors08/31/2019
- Review ArticleThe Association Between benzodiazepine (cas 12794-10-4)s and Survival in Patients With Cancer: A Systematic Review08/30/2019
- 7New benzodiazepine (cas 12794-10-4)s for sedation08/29/2019
- ReviewThe epidemiology of benzodiazepine (cas 12794-10-4) misuse: A systematic review08/27/2019


